Skip to main content
Equibles

GOLDMAN SACHS GROUP INC

Position in LLY — ELI LILLY & Co

CIK 886982 NEW YORK, NY
Back to LLY Full portfolio

Position in LLY

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$9,179,190,573
+$3,347,053,176 QoQ
Shares Held
7,652,960
+20.7% QoQ
Ownership
0.813%
of shares outstanding
% of Portfolio
1.11%
of 13F equity value
Holder Rank
#20
of 4,605 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 92% Shared 0% None 7%

Common Shares in LLY Over Time

Shares Held

Position Value (USD)

Derivatives in LLY

reported options exposure · as of Jun 30, 2026
CallValue
$246,123,055
CallShares
205,200
PutValue
$697,588,546
PutShares
581,600

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Jun 30, 2026

GOLDMAN SACHS GROUP INC holds $29,799,350,964 across 16 Drug Manufacturers - General names. LLY ranks #1 (30.8% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 LLY
ELI LILLY & Co
This page 		7,652,960 $9,179,190,573
2 JNJ
Johnson & Johnson
 19,722,544 $5,008,934,496
3 ABBV
AbbVie Inc.
 16,291,630 $4,099,625,769
4 MRK
Merck & Co., Inc.
 22,075,139 $2,836,655,359
5 AZN
Astrazeneca PLC
 9,742,396 $1,847,353,128
6 AMGN
Amgen Inc
 4,130,732 $1,495,820,670
7 GILD
Gilead Sciences, Inc.
 10,778,294 $1,361,729,661
8 PFE
Pfizer Inc
 52,991,850 $1,276,043,746

All Filings in LLY

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $697,588,546 581,600
2026-06-30 $9,179,190,573 7,652,960
2026-06-30 $246,123,055 205,200
2026-03-31 $230,678,316 250,800
2026-03-31 $355,767,036 386,800
2026-03-31 $5,832,137,397 6,340,865
2025-12-31 $631,159,622 587,300
2025-12-31 $614,502,081 571,800
2025-12-31 $6,394,232,676 5,949,894
2025-09-30 $444,905,300 583,100
2025-09-30 $632,984,800 829,600
2025-09-30 $5,077,616,978 6,654,806
2025-06-30 $166,741,467 213,900
2025-06-30 $4,288,436,961 5,501,311
2025-06-30 $156,997,342 201,400
2025-03-31 $391,068,385 473,500
2025-03-31 $12,553,832 15,200
2025-03-31 $4,404,820,018 5,333,293
2024-12-31 $157,410,800 203,900
2024-12-31 $3,831,968,680 4,963,690
2024-12-31 $21,461,600 27,800
2024-09-30 $71,406,764 80,600
2024-09-30 $4,120,019,670 4,650,450
2024-09-30 $116,678,298 131,700
2024-06-30 $4,461,658,315 4,927,940
2024-06-30 $308,010,276 340,200
2024-06-30 $99,863,414 110,300
2024-03-31 $58,269,204 74,900
2024-03-31 $55,857,528 71,800
2024-03-31 $3,516,036,117 4,519,559
2023-12-31 $98,979,816 169,800
2023-12-31 $77,295,192 132,600
2023-12-31 $2,728,026,543 4,679,933
2023-09-30 $108,715,112 202,400
2023-09-30 $2,599,202,146 4,839,056
2023-09-30 $63,273,914 117,800
2023-06-30 $74,849,208 159,600
2023-06-30 $61,342,584 130,800
2023-06-30 $2,269,756,269 4,839,772
2023-03-31 $1,952,344,757 5,685,006
2023-03-31 $19,231,520 56,000
2023-03-31 $28,194,782 82,100
2022-12-31 $83,960,280 229,500
2022-12-31 $1,769,626,976 4,837,161
2022-12-31 $32,632,928 89,200
2022-09-30 $29,295,510 90,600
2022-09-30 $38,284,640 118,400
2022-09-30 $1,541,150,120 4,766,198
2022-06-30 $47,467,272 146,400
2022-06-30 $37,805,218 116,600

Report a Problem

Category
Description
Email (optional, for follow-up)